Celebrating SIDP's 35th Anniversary: The Evolving Landscape of Infectious Diseases

The interview with Erin McCreary, PharmD, BCIDP, and Mike Dudley, PharmD, explores the evolution, impact, and future direction of infectious diseases pharmacy, particularly through the lens of antimicrobial stewardship and the work of the Society of Infectious Diseases Pharmacists (SIDP). They begin by outlining their extensive experience in both clinical practice and industry, highlighting how the field has grown from a small group of specialists into a globally recognized discipline. Early on, infectious diseases pharmacists faced limited treatment options and were primarily focused on managing a narrow range of antibiotics, often under significant cost and access constraints within hospitals.

As the pharmaceutical landscape expanded in the 1980s and 1990s, the introduction of new antibiotics and changes in hospital reimbursement models created both opportunities and challenges. These shifts emphasized the need for specialized expertise, leading to the development of antimicrobial stewardship practices and the formation of SIDP. The organization was founded to ensure proper training, self-regulation, and evidence-based decision-making among pharmacists, helping to standardize care and improve patient outcomes. Over time, SIDP has played a central role in advancing education, certification, and research in infectious diseases pharmacy.

Despite significant progress, many core challenges remain. McCreary and Dudley note that antimicrobial resistance has become far more complex, requiring deeper scientific understanding and more sophisticated approaches to treatment. Advances in pharmacokinetics and pharmacodynamics have improved how drugs are developed and used, but gaps still exist in areas such as dosing guidance for certain medications. Additionally, the demand for trained pharmacists continues to outpace the availability of residency programs, underscoring the need for expanded training infrastructure both in the United States and globally.

The role of infectious diseases pharmacists has also broadened considerably. What began as a hospital-based specialty has expanded into diverse practice settings, including outpatient care, industry, research, and global health initiatives. Pharmacists are now involved in everything from tuberculosis advocacy to complex oral therapies and system-wide clinical leadership. Regulatory changes, such as antimicrobial stewardship requirements, have further elevated the profession, making these experts essential to health care systems and patient safety efforts.

Looking ahead, the interview highlights emerging therapies and ongoing challenges in drug development and access. Innovations such as antivirals, nontraditional antimicrobial approaches, and potentially individualized treatments like phage therapy offer promise, but issues with the antibiotic pipeline and reimbursement models persist. Both McCreary and Dudley emphasize the importance of better articulating the value of antibiotics to ensure patient access to the most effective treatments. The infectious diseases field continues to evolve, driven by a commitment to optimizing antimicrobial use, improving patient care, and adapting to an increasingly complex global health landscape.